The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.
Among patients with psoriasis who did not achieve Psoriasis Area and Severity Index 50 during the first course of alefacept therapy, 53% achieved Psoriasis Area and Severity Index 50 during the second course (odds ratio [95% confidence interval] vs placebo 2.30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses.
Menter
Alan
A
Baylor University Medical Center, Dallas, Texas, USA. amresearch@texasderm.com
Cather
Jennifer C
JC
Baker
Diane
D
Farber
Harold F
HF
Lebwohl
Mark
M
Darif
Mohamed
M
D000077944:Alefacept; D002908:Chronic Disease; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D019233:Retreatment; D012720:Severity of Illness Index; D017211:Treatment Failure; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D000077944:Alefacept